Background: Biomarkers in cerebrospinal fluid (CSF) are crucial for diagnosing, monitoring, and prognosing neurological disorders.
Purpose: This study evaluates the impact of preanalytical variables, particularly container choice, on CSF protein measurements.
Analysis: Using 30 CSF samples, we compared sterile, additive-free tubes and lithium heparin tubes without separator gel.
Results: Protein levels were significantly elevated higher in heparin tubes (mean difference: 230.71 mg/dL, P < .001).
Conclusions: This overestimation underscores the necessity of adhering to preanalytical protocols to avoid erroneous clinical interpretations and ensure accurate diagnostic outcomes.
PlebaniM. Errors in clinical laboratories or errors in laboratory medicine?Clin Chem Lab Med2006; 44(6): 750–759. DOI: 10.1515/CCLM.2006.123.
2.
VosSJBVisserPJVerheyF, et al.Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice. PLoS One2014; 9: e100784. DOI: 10.1371/journal.pone.0100784.
3.
ShawLMAriasJ, et al.Cerebrospinal fluid biomarker measures: preanalytical variables and handling. Alzheimer’s Dementia2018; 14(6): 913–924. DOI: 10.1016/j.jalz.2018.04.002.
4.
ZetterbergHBlennowK. Fluid biomarkers for mild traumatic brain injury and related conditions. Nat Rev Neurol2016; 12(10): 563–574. DOI: 10.1038/nrneurol.2016.127.
5.
RifaiNHorvathARWittwerCT. Principles and applications of clinical mass spectrometry: small molecules, peptides, and pathogens. Amsterdam: Elsevier, 2018.
6.
YangJ-YChienT-ILuJ-Y, et al.Heparin interference in the cerebrospinal fluid protein assay measured with a pyrogallol red–molybdate complex. Clin Chim Acta2009; 408(Issues 1–2): 75–78. DOI: 10.1016/j.cca.2009.07.011.
7.
CabanillasLMda SilvaMAMarinsaldiA, et al.Interferencia de heparina en la determinación de proteínas totales por el método de Bradford. Revista Científica ANMAT2023; 4: e40. DOI: 10.62035/rca.4.40.
8.
PetzoldA. CSF biomarkers for improved prognostic accuracy in acute CNS disease. Neurol Res2007; 29(7): 691–708. DOI: 10.1179/016164107X240080.
9.
CLSI. Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays; approved guideline—fifth edition. Wayne, PA: CLSI, 2008. CLSI Document H21-A5.
10.
LiMZhaoMGaoY. Changes of proteins induced by anticoagulants can be more sensitively detected in urine than in plasma. Sci China Life Sci2014; 57: 649–656. DOI: 10.1007/s11427-014-4661-y.
11.
HanssonOMikulskisAFaganAM, et al.The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: a review. Alzheimers Dement2018; 14(10): 1313–1333. DOI: 10.1016/j.jalz.2018.05.008.
12.
CicognolaCChiasseriniDParnettiL. Preanalytical confounding factors in the analysis of cerebrospinal fluid biomarkers for Alzheimer’s disease: the issue of diurnal variation. Front Neurol2015; 6: 143. DOI: 10.3389/fneur.2015.00143.
